Br J Ophthalmol 1999;83:847-851 ( July )
Soluble ICAM-1 serum levels in patients with intermediate uveitis
Anne-Marie Kloka b c, Leny Luyendijka, Michel J W Zaalb, Aniki Rothovad, Aize Kijlstraa c
a Department
Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute,
Amsterdam, b Department of Ophthalmology, Free University,
Amsterdam, c Department of Ophthalmology, University of
Amsterdam, Amsterdam, d Department
of Ophthalmology, University of Utrecht, Utrecht
Correspondence to: Anne-Marie Klok, Department
Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute,
Amsterdam, PO Box 12141, 1100 AC Amsterdam, Netherlands.
Accepted for publication 12 January 1999
AIM
To investigate
whether serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) can serve as a marker of the presence of systemic disease in
intermediate uveitis.
METHODS
In a
multicentre study sICAM-1 serum levels were measured in 61 patients
with idiopathic intermediate uveitis, controls included 56 uveitis
patients with a systemic disease (26 sarcoid associated uveitis and 30 HLA-B27 positive acute anterior uveitis), 58 uveitis patients without
systemic disease (30 toxoplasma chorioretinitis and 28 Fuchs'
hetrochromic cyclitis), and 21 normal controls. The clinical records of
the patients with intermediate uveitis were analysed for disease
characteristics at the time of blood sampling and for a relation with
the development of a systemic disease after a mean follow up of 4.5 years.
RESULTS
Increased
serum levels of sICAM-1 were found in 34 out of 61 patients with
intermediate uveitis and were significantly different when compared
with toxoplasmosis, Fuchs' cyclitis, and healthy controls (p<0.001).
Elevated sICAM-1 levels were also found in 18 out of 26 patients with
sarcoid uveitis and in 11 out of 30 patients with HLA-B27 associated
anterior uveitis. Raised sICAM-1 levels in the intermediate uveitis
group were significantly associated with active ocular disease
(p<0.01) and the presence of vitreous exudates (p<0.05). Increased
levels of sICAM-1 correlated with interleukin 8 levels (IL-8) (tested
in a previous study in the same group of intermediate uveitis patients)
in patients with active systemic involvement. Follow up of the patients
showed that an established or suspected systemic disease was found more often in the 21 intermediate uveitis patients with increased sICAM-1 and IL-8 levels compared with the other 40 patients with intermediate uveitis (p<0.01).
CONCLUSIONS
The
measurement of both sICAM-1 and IL-8 can be used as a marker for ocular
disease activity and for a predisposition of developing an associated
systemic disease in intermediate uveitis patients.
© 1999 by British Journal of Ophthalmology